Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share (the "Common Stock")
-
Shares outstanding
-
62,650,155
-
Total 13F shares
-
48,874,647
-
Share change
-
-2,677,588
-
Total reported value
-
$445,736,286
-
Put/Call ratio
-
58%
-
Price per share
-
$9.12
-
Number of holders
-
190
-
Value change
-
-$14,688,112
-
Number of buys
-
97
-
Number of sells
-
95
Institutional Holders of Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE) as of Q2 2025
As of 30 Jun 2025,
Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE) was held by
190 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
48,874,647 shares.
The largest 10 holders included
Madison Avenue Partners, LP, BlackRock, Inc., VANGUARD GROUP INC, Hudson Bay Capital Management LP, D. E. Shaw & Co., Inc., Balyasny Asset Management L.P., GEODE CAPITAL MANAGEMENT, LLC, ALPINE ASSOCIATES MANAGEMENT INC., STATE STREET CORP, and 683 Capital Management, LLC.
This page lists
190
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.